The Children’s Oncology Group (COG) is the world’s largest organization devoted exclusively to childhood and adolescent cancer research. The COG unites more than 9,000 experts in childhood cancer at more than 220 leading children’s hospitals, universities, and cancer centers across North America, Australia, New Zealand, and Europe. Today, more than 90% of the 14,000 children and adolescents diagnosed with cancer each year in the United States are cared for at COG member institutions. The COG research has turned childhood cancer from a virtually incurable disease 50 years ago to one with a combined 5-year survival rate of 80% today. COG’s goal is to cure all children and adolescents with cancer, reduce the short and long-term complications of cancer treatments, and find ways to prevent childhood cancer.
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice), also known as Pediatric MATCH, is a pediatric precision medicine cancer treatment trial that explores whether targeted therapies can be effective for children and adolescents with solid tumors that harbor specific gene mutations. Pediatric MATCH is a phase 2 trial that will investigate more than eight different study drugs, each targeting a defined set of gene mutations, in order to match patients with therapies aimed at the molecular abnormalities in his or her tumor. G9 is the first private foundation to provide financial support to Pediatric MATCH.
Project:EveryChild is centered on a single research study capturing the biology and outcome of every child with cancer cared for in a COG program (more than 220 programs internationally). Participation is offered to every child diagnosed with cancer, no matter how common or rare the cancer may be. Key clinical data on disease presentation, therapeutic approach and outcome leverages the COG infrastructure. Although many children are also offered the opportunity to enroll in a COG therapeutic study, such enrollment is not be a requirement. Biospecimens, including tumor tissue are be stored at COG’s state-of-the-art biorepository located at The Research Institute of Nationwide Children’s Hospital (the largest pediatric cancer biospecimen bank in the nation).